275 related articles for article (PubMed ID: 26020795)
1. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
2. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
3. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.
Yan H; Gu W; Yang J; Bi V; Shen Y; Lee E; Winters KA; Komorowski R; Zhang C; Patel JJ; Caughey D; Elliott GS; Lau YY; Wang J; Li YS; Boone T; Lindberg RA; Hu S; Véniant MM
J Pharmacol Exp Ther; 2009 Apr; 329(1):102-11. PubMed ID: 19129372
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.
Kostic A; King TA; Yang F; Chan KC; Yancopoulos GD; Gromada J; Harp JB
Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409
[TBL] [Abstract][Full Text] [Related]
5. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
Omar BA; Andersen B; Hald J; Raun K; Nishimura E; Ahrén B
Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
[TBL] [Abstract][Full Text] [Related]
8. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.
Wang MY; Yan H; Shi Z; Evans MR; Yu X; Lee Y; Chen S; Williams A; Philippe J; Roth MG; Unger RH
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2503-8. PubMed ID: 25675519
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
10. Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice.
Lang S; Wei R; Wei T; Gu L; Feng J; Yan H; Yang J; Hong T
Peptides; 2020 Sep; 131():170349. PubMed ID: 32561493
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
Mani BK; Uchida A; Lee Y; Osborne-Lawrence S; Charron MJ; Unger RH; Berglund ED; Zigman JM
Diabetes; 2017 Jul; 66(7):1847-1857. PubMed ID: 28487437
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice.
Kim WD; Lee YH; Kim MH; Jung SY; Son WC; Yoon SJ; Lee BW
PLoS One; 2012; 7(12):e50954. PubMed ID: 23226550
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes.
Neumann UH; Ho JSS; Chen S; Tam YYC; Cullis PR; Kieffer TJ
Mol Metab; 2017 Oct; 6(10):1161-1172. PubMed ID: 29031717
[TBL] [Abstract][Full Text] [Related]
14. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.
Lang S; Yang J; Yang K; Gu L; Cui X; Wei T; Liu J; Le Y; Wang H; Wei R; Hong T
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139602
[TBL] [Abstract][Full Text] [Related]
15. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.
Lau YY; Ma P; Gibiansky L; Komorowski R; Wang J; Wang G; Yan H; Véniant MM; Kakkar T
AAPS J; 2009 Dec; 11(4):700-9. PubMed ID: 19851873
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.
Mu J; Jiang G; Brady E; Dallas-Yang Q; Liu F; Woods J; Zycband E; Wright M; Li Z; Lu K; Zhu L; Shen X; Sinharoy R; Candelore ML; Qureshi SA; Shen DM; Zhang F; Parmee ER; Zhang BB
Diabetologia; 2011 Sep; 54(9):2381-91. PubMed ID: 21695571
[TBL] [Abstract][Full Text] [Related]
18. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.
Gelling RW; Du XQ; Dichmann DS; Romer J; Huang H; Cui L; Obici S; Tang B; Holst JJ; Fledelius C; Johansen PB; Rossetti L; Jelicks LA; Serup P; Nishimura E; Charron MJ
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1438-43. PubMed ID: 12552113
[TBL] [Abstract][Full Text] [Related]
19. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
[TBL] [Abstract][Full Text] [Related]
20. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
